Core Viewpoint - He Yuan Biotechnology (Shanghai) Co., Ltd. forecasts a net loss of between 237 million yuan and 195 million yuan for 2025, representing a reduction in losses by 84.81 million yuan to 127 million yuan compared to the previous year [1] Group 1: Company Performance - The company has been deeply engaged in the cell and gene therapy (CGT) field for over a decade, developing core technology clusters for vector development, production processes, and quality control [1] - As of the end of 2025, He Yuan has assisted clients in obtaining over 60 clinical trial approvals, with 14 approvals granted by the U.S. Food and Drug Administration [1] - The company has established a million-level cell bank with one-click access and full visual management, along with 14 fully automated production lines in the regenerative medicine sector [1] Group 2: Technological Advancements - Continuous investment in technology has created a differentiated competitive barrier for the company [2] - In 2025, He Yuan's viral vector upgrades, including the VPack packaging system and AAV-PANX products, are expected to achieve high production [2] - The company has introduced proprietary technologies in gene editing and nucleic acid delivery, including the micro-light gene Cas12 protein and LNP-mRNA delivery system licensing [2] Group 3: Industry Position - Analysts indicate that He Yuan, with its comprehensive service capabilities and scalable delivery systems, has secured a favorable position in the CGT industrialization process [2] - The company's ongoing investments in technology, production capacity, and ecosystem collaboration are expected to further solidify its industry-leading position and contribute to the long-term development of the cell and gene therapy sector [2]